Bioidentical Hormone Therapy: What to Know

"Bioidentical" hormone therapy is a widely used marketing term, and it can mean different things. This page explains, in neutral terms, what the term refers to, where evidence and marketing claims diverge, how such therapy is generally used and monitored, and the considerations to discuss with a clinician.

What "bioidentical" means

The word "bioidentical" is generally used to describe hormones that have the same molecular structure as the hormones the human body produces, such as estradiol and progesterone. An important point often lost in marketing is that many regulated, well-studied hormone products approved by medicines regulators already use such structurally identical hormones. In other words, "bioidentical" describes the structure of a molecule; it does not, by itself, indicate that a product is safer, more natural, or more effective than other options.

In practice, the term is most often associated with two quite different things. The distinction below matters more than the word itself, because it determines how much is known about a given product's quality and dose.

So a hormone can be "bioidentical" in structure whether it sits in a routinely approved product or in a custom-compounded one. The two are not the same thing, and conflating them is a common source of confusion.

Where marketing claims outpace the evidence

Marketing for some compounded "bioidentical" products has promoted them as natural, individually tailored, and safer than conventional hormone therapy. Major medical and regulatory organizations have cautioned that these claims generally go beyond what the evidence supports. Key points commonly raised include:

• "Natural" is a marketing label, not a measure of safety. Hormones with the same structure as the body's own can still carry the considerations that apply to hormone therapy in general.
• Custom-compounded products are not generally subject to the same regulatory review as approved medicines, so their consistency, purity, and dose can be less certain.
• Saliva or blood "hormone level" testing to customize compounded therapy has been questioned by professional bodies, which note that such testing is not generally a reliable basis for tailoring treatment in this way.
• Claims of being free of the risks of standard therapy are not established. There is no good evidence that compounded bioidentical products are safer than approved options, and they may carry added uncertainty.
• Pellets and other novel delivery forms are sometimes promoted heavily; these still deliver active hormones, and the same general considerations and the question of regulatory oversight apply.

Because of these concerns, several professional organizations generally favor approved, regulated hormone products — many of which use structurally identical hormones — when hormone therapy is appropriate. This is an area where it is especially worth separating marketing language from clinical evidence.

Who hormone therapy may be considered for

When hormone therapy is being considered at all, it is generally after a clinical assessment and a clear diagnosis, for symptoms or conditions linked to hormone changes, such as bothersome menopausal symptoms. The decision weighs symptoms, age and time since menopause, personal and family history, and individual risks. Whether a given product is labeled "bioidentical" is less important than whether the specific therapy is appropriate, well studied, and suitable for the individual. A diagnosis-first approach helps keep the focus on whether treatment is warranted, rather than on a marketing category.

How it is generally used and monitored

Hormones described as bioidentical are delivered in the same general ways as other hormone therapy — for example, tablets, skin patches or gels, or vaginal preparations for estrogen, and oral or other forms for progesterone. Monitoring follows the same principles as for hormone therapy generally: clinicians review how symptoms respond, reassess periodically, ask about any new or unexpected bleeding, keep routine health screening up to date, and discuss whether to continue.

As noted above, routine saliva or blood hormone testing to fine-tune compounded products is not generally considered a reliable approach, and professional bodies have cautioned against using it as the basis for adjusting therapy. This page does not give doses, which are individualized. The general principle is planned, regular review rather than treatment that is set and left unchanged.

Considerations and risks

The considerations for therapy using structurally identical hormones are broadly those of hormone therapy in general, which differ by the hormone, route, whether a progestogen is included, and the person's age and history. These can include effects discussed for estrogen and progestogens, such as those on blood clots and breast tissue, depending on the specifics. With compounded products in particular, there is the added uncertainty of less regulatory oversight regarding consistency and dose — meaning the amount actually delivered may be less predictable.

Some people have conditions that make hormone therapy unsuitable or that call for caution. Because of all this, the choice is individualized and reviewed with a clinician, and unsupported claims of superior safety are best treated with caution. The most useful question is not whether a product is called "bioidentical," but whether it is appropriate, of known quality, and suitable for the individual.

Shared decision-making

Choosing whether to use hormone therapy, and which product, is a personal decision made together with a clinician who can weigh the evidence for a specific option against your history and goals. A grounded conversation often covers what the marketing claims actually mean, whether an approved product would serve the same purpose, what is known about a compounded option's quality, and how the plan will be reviewed. Explore related material in our conditions and hormones sections, learn about testing under blood tests, and see related options such as estrogen therapy and progesterone therapy in the treatments overview.